Urinary Bladder Neoplasms
"Urinary Bladder Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the URINARY BLADDER.
| Descriptor ID |
D001749
|
| MeSH Number(s) |
C04.588.945.947.960 C12.758.820.968 C12.777.829.813 C13.351.937.820.945 C13.351.968.829.707
|
| Concept/Terms |
Urinary Bladder Neoplasms- Urinary Bladder Neoplasms
- Neoplasm, Urinary Bladder
- Urinary Bladder Neoplasm
- Neoplasms, Bladder
- Bladder Neoplasms
- Bladder Neoplasm
- Neoplasm, Bladder
- Bladder Tumors
- Bladder Tumor
- Tumor, Bladder
- Tumors, Bladder
Urinary Bladder Cancer- Urinary Bladder Cancer
- Cancer, Urinary Bladder
- Malignant Tumor of Urinary Bladder
- Cancer of the Bladder
- Bladder Cancer
- Bladder Cancers
- Cancer, Bladder
- Cancer of Bladder
|
Below are MeSH descriptors whose meaning is more general than "Urinary Bladder Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Urinary Bladder Neoplasms".
This graph shows the total number of publications written about "Urinary Bladder Neoplasms" by people in this website by year, and whether "Urinary Bladder Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 5 | 0 | 5 |
| 1994 | 4 | 1 | 5 |
| 1995 | 2 | 3 | 5 |
| 1996 | 3 | 1 | 4 |
| 1997 | 4 | 0 | 4 |
| 1998 | 6 | 0 | 6 |
| 1999 | 5 | 1 | 6 |
| 2000 | 2 | 0 | 2 |
| 2001 | 7 | 0 | 7 |
| 2002 | 10 | 0 | 10 |
| 2003 | 4 | 0 | 4 |
| 2004 | 3 | 0 | 3 |
| 2005 | 2 | 2 | 4 |
| 2006 | 5 | 2 | 7 |
| 2007 | 10 | 0 | 10 |
| 2008 | 8 | 0 | 8 |
| 2009 | 6 | 0 | 6 |
| 2010 | 9 | 0 | 9 |
| 2011 | 16 | 2 | 18 |
| 2012 | 13 | 1 | 14 |
| 2013 | 12 | 0 | 12 |
| 2014 | 16 | 0 | 16 |
| 2015 | 14 | 0 | 14 |
| 2016 | 10 | 0 | 10 |
| 2017 | 14 | 1 | 15 |
| 2018 | 13 | 1 | 14 |
| 2019 | 17 | 0 | 17 |
| 2020 | 14 | 1 | 15 |
| 2021 | 7 | 2 | 9 |
| 2022 | 11 | 0 | 11 |
| 2023 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Urinary Bladder Neoplasms" by people in Profiles.
-
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE). Eur Urol Focus. 2023 07; 9(4):561-563.
-
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy. Clin Cancer Res. 2023 06 01; 29(11):2052-2065.
-
Outcomes of Hematuria Evaluation by Advanced Practice Providers and Urologists. Urology. 2023 Aug; 178:67-75.
-
Use of a physical activity monitor to track perioperative activity of radical cystectomy patients. Our first glimpse at what our patients are doing before and after surgery. Urol Oncol. 2023 04; 41(4):206.e11-206.e19.
-
Novel cryotherapy in non-muscle-invasive bladder cancer. Cancer. 2023 02 01; 129(3):333-334.
-
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol. 2023 03; 34(3):289-299.
-
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nat Commun. 2022 11 04; 13(1):6658.
-
Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma. Sci Adv. 2022 10 07; 8(40):eabo8043.
-
Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab. Mod Pathol. 2022 11; 35(11):1529-1539.
-
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). J Clin Oncol. 2023 01 01; 41(1):43-53.